No material company-specific news briefings were available for Amgen Inc. in the 30-day period leading to this report's generation date of 5 October 2026. The report was triggered by material institutional position changes identified in recent 13F filings [Brief - 2026-09-27].
Amgen's trailing twelve-month revenue as of 30 June 2026 stood at $38.10 billion, representing year-over-year growth of 9.5% [SEC 10-Q - AMGN - 2026-06-30]. Net income for the same period was $8.74 billion, with a net margin of 22.95% and an operating margin of 29.99%. Gross margin was recorded at 47.46%. Earnings per share grew 64.91% year-over-year. The company held $13.99 billion in cash against total debt of $59.30 billion. Market capitalisation was approximately $217.88 billion, and the trailing P/E ratio stood at 25.05 [SEC 10-Q - AMGN - 2026-06-30].
Several institutional holders made notable position changes in their most recent 13F filings. Citadel added approximately 60% to its existing AMGN position [SEC 13F - Citadel - Q2 2026]. AQR Capital nearly doubled its holding, increasing its position by approximately 97% [SEC 13F - AQR Capital - Q2 2026]. Bridgewater added approximately 48% to its position [SEC 13F - Bridgewater - Q2 2026]. In contrast, Millennium Management reduced its position by approximately 36% [SEC 13F - Millennium - Q2 2026]. No insider transactions were available in the provided data for this reporting period.
The prevailing macroeconomic backdrop includes a 10-year US Treasury yield of 5.24% and a 2-year yield of 4.78%, reflecting a normal yield curve shape [FRED DGS10] [FRED DGS2]. Elevated long-duration rates are a factor in the broader equity and debt financing environment, relevant context given Amgen's total debt position of $59.30 billion as of the most recent quarterly filing [SEC 10-Q - AMGN - 2026-06-30].